Network origin in Mauro Giacca first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Forcefield Therapeutics Ltd.
3
| Private Company | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mauro Giacca via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman Chairman | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
| BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Private Equity Investor | |
| Washington University in St. Louis | College/University | Undergraduate Degree | |
| University of Louisville School of Medicine | College/University | Doctorate Degree | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Director/Board Member | |
| Syncona Ip Holdco Ltd. | Director/Board Member | ||
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chairman | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Founder | |
| University of Cambridge | College/University | Doctorate Degree | |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| London School of Economics & Political Science | College/University | Graduate Degree |
Statistics
International
| United Kingdom | 16 |
| United States | 10 |
| Switzerland | 2 |
Sectoral
| Health Technology | 15 |
| Consumer Services | 5 |
| Finance | 3 |
| Commercial Services | 3 |
| Health Services | 2 |
Operational
| Director/Board Member | 11 |
| Chairman | 9 |
| Private Equity Investor | 5 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 3 |
Most connected contacts
| Insiders | |
|---|---|
| Chris Hollowood | 18 |
| John Tsai | 10 |
| Alice Renard | 3 |
- Stock Market
- Insiders
- Mauro Giacca
- Company connections